Literature DB >> 17330205

Remote ischemic preconditioning modulates p38 MAP kinase in rat adipocutaneous flaps.

R Brannon Claytor1, Nathan J Aranson, Ronald A Ignotz, Janice F Lalikos, Raymond M Dunn.   

Abstract

Ischemic preconditioning has been shown to improve survival of cutaneous flaps. The authors examined the effect of remote ischemic preconditioning (RIPC) on phosphorylation of p38 MAP kinase and related the results to flap survival. Female Wistar rats had 8 x 12-cm abdominal adipocutaneous flaps raised on the medial branch of the superficial epigastric artery. Controls (Group 1) had the flap elevated and the pedicle clamped for 3 hr, then closed with a sheet of plastic between the flap and abdominal wall. Group 2 animals had RIPC by tourniquet on the contralateral hind limb before the flap was dissected. Group 3 animals mimicked Group 2 and also had an infusion of the nitric oxide blocker, N-nitro-L-arginine methyl ester (L-NAME) 5 min prior to the RIPC. Group 4 had the flap elevated prior to the RIPC. All groups except Group 1 had 10 min of RIPC with 30 min of reperfusion, then 3 hr of ischemia. Tissue samples were taken at the distal margins of the flaps before preconditioning and 30 min after preconditioning for detection of p38 MAP kinase and phosphorylated p38 MAP kinase (pp38 MAP kinase). Group 2 flaps (RIPC before flap elevation) exhibited better flap tissue survival and had well-defined phosphorylation of p38 MAP kinase 30 min post RIPC, when compared to the other groups. Pre-infusion with the nitric oxide blocker (Group 3) before RIPC blocked the survival advantage conferred by preconditioning and diminished the phosphorylation of p38 MAP kinase. Tissue from all groups showed very little phosphorylation of p38 MAP kinase following 3 hr of ischemia. Thus, increased tissue survival is correlated with elevated levels of p38 MAP kinase phosphorylation following RIPC. This effect is inhibited by blockade of nitric oxide. Modulation of the p38 MAP kinase pathway may represent a protection pathway for ischemic preconditioning.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330205     DOI: 10.1055/s-2007-970189

Source DB:  PubMed          Journal:  J Reconstr Microsurg        ISSN: 0743-684X            Impact factor:   2.873


  7 in total

Review 1.  The Delay Phenomenon: A Compilation of Knowledge across Specialties.

Authors:  Kristy Hamilton; Erik M Wolfswinkel; William M Weathers; Amy S Xue; Daniel A Hatef; Shayan Izaddoost; Larry H Hollier
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-02-21

2.  Roles of MAPKAPK-2 and HSP27 in the reduction of renal ischemia-reperfusion injury by ischemic postconditioning in rats.

Authors:  Anzhou Xia; Yong Li; Na Li; Zhi Xue; Jieyun Xia; Tiantian Wei; Jing Cao
Journal:  Int Urol Nephrol       Date:  2014-06-14       Impact factor: 2.370

3.  Effects of ischemic conditioning on head and neck free flap oxygenation: a randomized controlled trial.

Authors:  Se-Hee Min; Suk Hyung Choe; Won Shik Kim; Soon-Hyun Ahn; Youn Joung Cho
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

4.  Superoxide dismutase/catalase mimetics but not MAP kinase inhibitors are neuroprotective against oxygen/glucose deprivation-induced neuronal death in hippocampus.

Authors:  Miou Zhou; Reymundo Dominguez; Michel Baudry
Journal:  J Neurochem       Date:  2007-09-14       Impact factor: 5.372

Review 5.  Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option?

Authors:  Natig Gassanov; Amir M Nia; Evren Caglayan; Fikret Er
Journal:  J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 10.121

6.  Remote Ischemic Preconditioning and Protection of the Kidney--A Novel Therapeutic Option.

Authors:  Alexander Zarbock; John A Kellum
Journal:  Crit Care Med       Date:  2016-03       Impact factor: 7.598

7.  An optimized low-pressure tourniquet murine hind limb ischemia reperfusion model: Inducing acute ischemia reperfusion injury in C57BL/6 wild type mice.

Authors:  Marius Drysch; Christoph Wallner; Sonja Verena Schmidt; Felix Reinkemeier; Johannes Maximilian Wagner; Marcus Lehnhardt; Björn Behr
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.